crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CR crane

Pre-Mkt 12-09 07:16:52 EST

187.50

-0.29

-0.15%

盘前189.18

+1.68+0.90%

06:00 EST

High189.39	Low186.06	Vol381.40K
Open186.87	D1 Closing187.79	Amplitude1.77%
Mkt Cap10.80B	Tradable Cap9.14B	Total Shares57.60M
T/O71.42M	T/O Rate0.78%	Tradable Shares48.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":187.5,"timestamp":1765227600000,"preClose":187.79,"halted":0,"volume":381398,"hourTrading":{"tag":"盘前","latestPrice":189.18,"preClose":187.5,"latestTime":"06:00 EST","volume":2,"amount":378.36,"timestamp":1765278043075},"delay":0,"floatShares":48764858,"shares":57596887,"eps":6.247815,"marketStatus":"Pre-Mkt","change":-0.29,"latestTime":"12-09 07:16:52 EST","open":186.87,"high":189.39,"low":186.06,"amount":71415989.82012,"amplitude":0.017733,"askPrice":189.15,"askSize":7,"bidPrice":186.57,"bidSize":8,"shortable":3,"etf":0,"ttmEps":6.247815,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765290600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":187.5,"dividendRate":0.004773,"preHourTrading":{"tag":"盘前","latestPrice":189.18,"preClose":187.5,"latestTime":"06:00 EST","volume":2,"amount":378.36,"timestamp":1765278043075},"postHourTrading":{"tag":"盘后","latestPrice":187.5,"preClose":187.5,"latestTime":"17:22 EST","volume":100837,"amount":18906935.2,"timestamp":1765232530353},"volumeRatio":1.0136872419374132,"impliedVol":0.2743,"impliedVolPercentile":0.1245},"requestUrl":"/m/hq/s/CR/tweets","defaultTab":"tweets","newsList":[{"id":"2590343065","title":"Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343065","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343065?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281600,"startTime":"0","endTime":"0","summary":"ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202225/0/en/Senti-Bio-Announces-Updated-SENTI-202-Clinical-Data-from-Ongoing-Phase-1-Trial-in-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-Patients-Demonstrating-Deep-MRD-Negative-Durable-Com.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","AEI","ODD","LD","LU0347712357.USD","ASH","IE00BYQQ9H92.USD","MTD","BK4533","BK4161","LU1093756325.SGD","BK4183","BK4567","BK4585","LU1093756168.USD","BK4588","LU2211817866.USD","BK4121","IE00BFXG0V08.USD","LU1721428933.USD","IE0009354923.USD","BK4109","BK4024","LU2413666699.HKD","CR","LU2413666426.HKD","ORR","BK4563","LU2463526074.USD"],"gpt_icon":0},{"id":"2590367742","title":"ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367742","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367742?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus patient","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202021/0/en/ASH-2025-Ascentage-Pharma-Presents-First-Dataset-from-Phase-III-POLARIS-1-Study-of-Olverembatinib-in-Newly-Diagnosed-Ph-ALL-Shows-a-Best-MRD-Negativity-CR-Rate-Exceeding-60.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4134","BK4588","LU2355687059.USD","EMA","BK4585","BK4107","ASH","BK4109","LU1699723380.USD","AAPG","ALL","BK4161","BK4081","BK4139","III","LU2463526074.USD","CR","LU1571399168.USD","LU0985320562.USD"],"gpt_icon":0},{"id":"2590910366","title":"Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590910366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590910366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201984/0/en/Genmab-Announces-New-Data-from-Phase-1b-2-EPCORE-CLL-1-Highlighting-Potential-of-Epcoritamab-as-Monotherapy-and-in-Combination-for-Patients-with-Richter-Transformation-RT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","ORR","IE00B7SZL793.SGD","OS","LU0963586101.USD","IE00B19Z4B17.USD","LU2065731478.USD","LU2463526074.USD","BK4097","BK4161","BK4195","CRS","ASH","CR","PFS","BK4109","IE0031619046.USD","BK4006","IE00B66KJ199.SGD","BK4187"],"gpt_icon":0},{"id":"2589355106","title":"Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355106?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:35","pubTimestamp":1765200900,"startTime":"0","endTime":"0","summary":"Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201559/0/en/Autolus-Therapeutics-Presents-Initial-Clinical-Data-in-Pediatric-r-r-B-ALL-Patients-and-Other-Oncology-Data-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","LU2463526074.USD","BK4117","LU0985320562.USD","LU1699723380.USD","BK4097","BK4022","ORR","LU2355687059.USD","IE00B7SZL793.SGD","LU2065731478.USD","UCL","IE00B19Z4B17.USD","BK4123","BK4187","BK4006","BK4107","FC","BK4539","IE0031619046.USD","LU1571399168.USD","BK4007","LENZ","BK4109","CRS","ALL","BK4585","CAR","CR","ASH","AFG","LU0963586101.USD","BK4139","IE00B66KJ199.SGD","BK4230","OS","BK4161","BK4533","BK4588"],"gpt_icon":0},{"id":"2589533799","title":"Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533799","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589533799?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:50","pubTimestamp":1765194600,"startTime":"0","endTime":"0","summary":"– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute le","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201378/0/en/Syndax-Highlights-Leadership-in-Menin-Inhibition-at-ASH-2025-with-Multiple-Revuforj-revumenib-Presentations-Spanning-the-Acute-Leukemia-Treatment-Continuum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4107","CR","OS","LU1571399168.USD","LU1699723380.USD","LU0985320562.USD","BK4129","ALL","BK4109","LU2355687059.USD","BK4585","BK4161","ECG","LU2463526074.USD","BK4097","HSCT","BK4533","ASH","BK4588"],"gpt_icon":0},{"id":"2589828533","title":"ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589828533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589828533?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:30","pubTimestamp":1765175400,"startTime":"0","endTime":"0","summary":"Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201199/0/en/ASH-2025-Cellectis-Presents-Development-Plan-to-Further-Enhance-High-Response-Rate-Observed-for-Eti-cel-in-r-r-NHL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","BK4161","LU2463526074.USD","ORR","BK4139","ASH","CLLS","CR"],"gpt_icon":0},{"id":"2589801826","title":"At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801826","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801826?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149300,"startTime":"0","endTime":"0","summary":"– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201155/0/en/At-ASH-2025-Oral-Presentation-Immix-Biopharma-Reports-Positive-Phase-2-NXC-201-Results-Advancing-Toward-BLA-Submission-as-a-Potentially-First-and-Best-in-Class-Therapy-for-relapsed.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","CR","BK4183","KOL","BK4572","BK4109","ODD","LU2463526074.USD","BK4104","IE0034390439.USD","BK4230","IE0009354923.USD","AL","NXC","ASH","BK4022","LU1169590202.USD","BK4161","LU1169589451.USD","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2589877324","title":"ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877324","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877324?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:00","pubTimestamp":1765112400,"startTime":"0","endTime":"0","summary":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an appr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX","BK4231","BK4211","BK4109","BK4097","BK4213","ORR","PR","BK4124","OS","LU2463526074.USD","BK4161","BK4195","PFS","ASH","CR","BK4080","SMP"],"gpt_icon":0},{"id":"2589187279","title":"Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589187279","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589187279?lang=en_us&edition=fundamental","pubTime":"2025-12-07 20:50","pubTimestamp":1765111800,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201123/0/en/Genmab-Presents-Pivotal-Phase-3-Data-from-EPCORE-FL-1-Trial-Demonstrating-Clinical-Benefit-of-EPKINLY-epcoritamab-bysp-in-Combination-with-Rituximab-and-Lenalidomide-R2-in-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","ASH","LU2463526074.USD","CR","BK4161","BK4109","BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2589261588","title":"Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261588?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in pat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201065/0/en/Genmab-Announces-Data-From-Multiple-Clinical-Trials-Showing-Treatment-with-Fixed-Duration-Epcoritamab-Led-to-Remissions-in-First-Line-Diffuse-Large-B-Cell-Lymphoma-DLBCL-and-Follic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","LU0390134368.USD","LU2065731478.USD","ORR","BK4187","IPI","BK4588","BR","BK4093","BK4161","BK4548","LU2463526074.USD","LU1228905540.USD","OS","IE0034235188.USD","BK4195","LU0545562505.USD","CR","BK4097","IE00B19Z4B17.USD","BK4226","BK4106","BK4585","LU0963586101.USD","PFS","BK4109","IE0009354923.USD","IE0031619046.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4006","CRS","LU1228905037.USD","ASH"],"gpt_icon":0},{"id":"2589550638","title":"Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589550638","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589550638?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:00","pubTimestamp":1764892800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  04, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCO","LU1221951046.USD","BK4560","LU2286300806.USD","LU0234572021.USD","IE00BFXG1179.USD","LU2237443382.USD","IE00BVYPNW00.USD","BK4134","CR","ASH","III","SG9999015986.USD","LU1221951129.SGD","IE00BZ1G4Q59.USD","LU0985320562.USD","LU1894683348.USD","BK4020","AAPG","LU1066051225.USD","LU1674673428.USD","IE00BFMHRM44.USD","LU1244550221.USD","LU0868494708.USD","BK4525","LU1599440770.SGD","LU0203347892.USD","ALL","LU1778281490.HKD","LU1929549753.HKD","OS","LU0792757196.USD","LU1880398471.USD","BK4585","IE00BDGV0183.EUR","EMA","LU0234570918.USD","LU0868494617.USD","LU1571399168.USD","BK4581","BK4139","BK4579","CDE","IE00B3PB1722.GBP","LU1244550577.SGD","LU0348723411.USD","LU2506952097.USD","BK4017","BK4161"],"gpt_icon":0},{"id":"2589983435","title":"Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2589983435","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589983435?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:53","pubTimestamp":1764874380,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics posts interim Phase 1 data showing antitumor activity and durable responses for PLN-101095 in ICI-refractory advanced cancer patients.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49217318/pliant-cancer-drug-boosts-responses-when-paired-with-mercks-blockbuster-keytruda-in-tough-to-treat-tumors","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49217318/pliant-cancer-drug-boosts-responses-when-paired-with-mercks-blockbuster-keytruda-in-tough-to-treat-tumors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1066051498.USD","LU1989772923.USD","LU1037948897.HKD","LU1291159041.SGD","PR","IE00BN8TJ469.HKD","LU0211331839.USD","MRK","LU1066053197.SGD","SG9999014567.USD","LU1162221912.USD","LU0070302665.USD","LU0266013472.USD","LU0320765646.SGD","LU1066051811.HKD","IE00B1BXHZ80.USD","LU0861579265.USD","CR","LU2023250504.SGD","LU0234572021.USD","IE00BSNM7G36.USD","LU1093756325.SGD","LU0238689110.USD","LU1093756168.USD","LU2361044865.SGD","LU1989772840.SGD","SG9999015358.SGD","LU2324357040.USD","BK4533","LU0058720904.USD","LU1035773651.USD","LU1983299246.USD","LU1934455277.USD","BK4550","LU0965509101.SGD","LU2461242641.AUD","BK4213","IE00BFTCPJ56.SGD","LU1974910355.USD","SG9999001176.SGD","LU0265550946.USD","SG9999002232.USD","SG9999013999.USD","IE000M9KFDE8.USD","SG9999001176.USD","LU1066051225.USD","LU0203345920.USD","PLRX","LU1116320901.HKD"],"gpt_icon":0},{"id":"2588889791","title":"Wolfe Research Initiates Coverage on Crane With Outperform Rating, $215 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2588889791","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588889791?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:14","pubTimestamp":1764850469,"startTime":"0","endTime":"0","summary":"Crane Company (CR) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2588029698","title":"Why Is ADC Therapeutics Plunging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2588029698","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588029698?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:40","pubTimestamp":1764790800,"startTime":"0","endTime":"0","summary":"Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, with enrollment ongoing into 2026.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/03/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/03/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PR","CR","ADCT","SD","BK4213","BK4007","BK4161","LENZ","ORR","BK4080","BK4231","BK4505","BK4139","BK4539","ADC"],"gpt_icon":0},{"id":"2588049527","title":"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049527","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588049527?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766800,"startTime":"0","endTime":"0","summary":"TARA-002 demonstrates 72% complete response rate at any time in BCG-Nave patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198842/0/en/Protara-Therapeutics-Announces-Updated-Interim-Data-from-Phase-2-ADVANCED-2-Trial-of-TARA-002-in-BCG-Na%C3%AFve-NMIBC-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4135","BCG","BK4523","IFN","TARA","CR","BK4139"],"gpt_icon":0},{"id":"2588504524","title":"Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2588504524","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588504524?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:30","pubTimestamp":1764765000,"startTime":"0","endTime":"0","summary":"Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustai","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198765/0/en/Relmada-Therapeutics-Announces-Presentation-of-NDV-01-Phase-2-Data-at-the-Society-for-Urologic-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4161","BK4539","CR","LENZ","BK4007"],"gpt_icon":0},{"id":"2586782177","title":"Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2586782177","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586782177?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:52","pubTimestamp":1764334320,"startTime":"0","endTime":"0","summary":"BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd.  announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel  , has received new drug marketing approvalfrom the China National Medical Products Administration . This approval is for the treatment of relapsed or refractory Large B-Cell Lymphoma  after two or more lines of systemic therapy. This is the second approved indicationin China for Ina-cel, following its initial approval in November 2023 for the treatment of adult relapsed or refractory B-cell Acute Lymphoblastic Leukemia . This milestone marks the first proprietary CD19 CAR-T product in China with full intellectual property rights to become the only CAR-T cell therapy product in the country that covers both leukemia and lymphoma, the two major hematological oncology indications.Professor Dehui Zou, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences :","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/inaticabtagene-autoleucel-yorwidatm-new-drug-application-for-lymphoma-approved-chinas-innovative-car-t-enters-a-new-era-of-dual-indications-302628059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4187","BK4006","IE0031619046.USD","BK7095","BK4022","CRS.AU","CRS","IE00B19Z4B17.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU2065731478.USD","ORR","LU0963586101.USD","ORR.AU","CAR","CR","BK4161"],"gpt_icon":0},{"id":"2584153997","title":"PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2584153997","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584153997?lang=en_us&edition=fundamental","pubTime":"2025-11-20 23:12","pubTimestamp":1763651520,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01  have been accepted for oral presentations at the 2025 American Society of Hematology  Annual Meeting.The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia  and r/r B-cell Non-Hodgkin Lymphoma , including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation studies  support BAFF-R as a differentiated target designed to overcome CD19 antigen escape while maintaining durable activity and low toxicity.Safety: PMB-CT01 demonstrated an exceptionally favorable tolerability profile. No Grade 1 Cytokine Release Syndrome  and no Grade 1 Immune Effector Cell-Associated Neu","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pepromene-bios-pmb-ct01-baffr-car-t-data-selected-for-two-oral-presentations-at-67th-ash-2025-annual-meeting-302621280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4230","BK4187","BK7111","BK7501","IE0031619046.USD","ASH.AU","IE00B66KJ199.SGD","CRS","IE00B19Z4B17.USD","IE00B7SZL793.SGD","CAR","ASH","BK4161","LU2463526074.USD","CRS.AU","HCT.AU","BK7057","BK7095","LU0963586101.USD","BK4109","CR","LU2065731478.USD","BK4006"],"gpt_icon":0},{"id":"1121790527","title":"Rare Adiantum reniforme var. sinense Wild Population Rediscovered in Three Gorges Reservoir Area","url":"https://stock-news.laohu8.com/highlight/detail?id=1121790527","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121790527?lang=en_us&edition=fundamental","pubTime":"2025-11-20 17:20","pubTimestamp":1763630452,"startTime":"0","endTime":"0","summary":"A research team from the Yangtze River Economic Belt Ecological Environment National Engineering Research Center under China Three Gorges Corporation has rediscovered critically endangered Adiantum...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2584906256","title":"Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584906256","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584906256?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:56","pubTimestamp":1763607360,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 , ATG-037 , and ATG-101 . The company will also share the latest progress on ATG-125 :A B7H3 x PD-L1 targeted therapy featuring\"IO + ADC\"dual-effect molecules for the treatment of solid tumors and its AnTenGagerT-cell engager  technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs.In addition, guest expert Prof. Xin Wang, Chief Physician, Drug Clinical Trial Center, National Cancer Center / Cancer Hospital of the Chinese Academy of Medica","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-hosts-2025-rd-day-showcasing-encouraging-clinical-data-and-solid-progress-with-investigational-programs-302621100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK4187","IND.AU","CRS.AU","IE00B7SZL793.SGD","BK7508","ACR","IE00B66KJ199.SGD","LU0963586101.USD","CR","CRS","LU2065732104.USD","PRGS","ACR.AU","ORR.AU","BK4161","BK4006","BK4110","LU2065731478.USD","BK4097","ORR","BK7096","IE0031619046.USD","IE00B19Z4B17.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.craneco.com","stockEarnings":[{"period":"1week","weight":0.0395},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.0048},{"period":"1year","weight":0.0631},{"period":"ytd","weight":0.2356}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.1368},{"period":"1year","weight":0.1247},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.021506},{"month":2,"riseRate":0.711111,"avgChangeRate":0.035546},{"month":3,"riseRate":0.577778,"avgChangeRate":0.017327},{"month":4,"riseRate":0.608696,"avgChangeRate":0.002531},{"month":5,"riseRate":0.630435,"avgChangeRate":0.008709},{"month":6,"riseRate":0.586957,"avgChangeRate":0.005131},{"month":7,"riseRate":0.586957,"avgChangeRate":0.004401},{"month":8,"riseRate":0.347826,"avgChangeRate":-0.009516},{"month":9,"riseRate":0.369565,"avgChangeRate":-0.022666},{"month":10,"riseRate":0.586957,"avgChangeRate":0.009396},{"month":11,"riseRate":0.543478,"avgChangeRate":0.025826},{"month":12,"riseRate":0.608696,"avgChangeRate":0.018461}],"exchange":"ARCA","name":"crane","nameEN":"crane"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"crane,CR,crane股票,crane股票老虎,crane股票老虎国际,crane行情,crane股票行情,crane股价,crane股市,crane股票价格,crane股票交易,crane股票购买,crane股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction